advertisement
Teister J 25
Showing records 1 to 25 | Display all abstracts from Teister J72797 Intravitreal injection of β-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma
Anders F
PLoS ONE 2017; 12: e0175451
73128 Proteomic profiling reveals crucial retinal protein alterations in the early phase of an experimental glaucoma model
Anders F
Graefe's Archive for Clinical and Experimental Ophthalmology 2017; 255: 1395-1407
73522 Modulation of the immune system for the treatment of glaucoma
Bell K
Current Neuropharmacology 2017; 0:
73546 Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
Teister J
Scientific reports 2017; 7: 6260
72797 Intravitreal injection of β-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma
Teister J
PLoS ONE 2017; 12: e0175451
73546 Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
Anders F
Scientific reports 2017; 7: 6260
73128 Proteomic profiling reveals crucial retinal protein alterations in the early phase of an experimental glaucoma model
Teister J
Graefe's Archive for Clinical and Experimental Ophthalmology 2017; 255: 1395-1407
73522 Modulation of the immune system for the treatment of glaucoma
Und Hohenstein-Blaul NVT
Current Neuropharmacology 2017; 0:
73128 Proteomic profiling reveals crucial retinal protein alterations in the early phase of an experimental glaucoma model
Funke S
Graefe's Archive for Clinical and Experimental Ophthalmology 2017; 255: 1395-1407
73522 Modulation of the immune system for the treatment of glaucoma
Teister J
Current Neuropharmacology 2017; 0:
72797 Intravitreal injection of β-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma
Liu A
PLoS ONE 2017; 12: e0175451
73546 Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
Beck S; Funke S
Scientific reports 2017; 7: 6260
73522 Modulation of the immune system for the treatment of glaucoma
Grus FH
Current Neuropharmacology 2017; 0:
72797 Intravitreal injection of β-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma
Funke S
PLoS ONE 2017; 12: e0175451
73128 Proteomic profiling reveals crucial retinal protein alterations in the early phase of an experimental glaucoma model
Pfeiffer N
Graefe's Archive for Clinical and Experimental Ophthalmology 2017; 255: 1395-1407
73546 Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
von Pein H
Scientific reports 2017; 7: 6260
73128 Proteomic profiling reveals crucial retinal protein alterations in the early phase of an experimental glaucoma model
Grus F
Graefe's Archive for Clinical and Experimental Ophthalmology 2017; 255: 1395-1407
72797 Intravitreal injection of β-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma
Grus FH
PLoS ONE 2017; 12: e0175451
73128 Proteomic profiling reveals crucial retinal protein alterations in the early phase of an experimental glaucoma model
Solon T
Graefe's Archive for Clinical and Experimental Ophthalmology 2017; 255: 1395-1407
72797 Intravitreal injection of β-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma
Thanos S
PLoS ONE 2017; 12: e0175451
73546 Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
Prokosch V
Scientific reports 2017; 7: 6260
72797 Intravitreal injection of β-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma
von Pein HD
PLoS ONE 2017; 12: e0175451
73128 Proteomic profiling reveals crucial retinal protein alterations in the early phase of an experimental glaucoma model
Prokosch V
Graefe's Archive for Clinical and Experimental Ophthalmology 2017; 255: 1395-1407
73546 Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
Pfeiffer N; Grus F
Scientific reports 2017; 7: 6260
72797 Intravitreal injection of β-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma
Pfeiffer N; Prokosch V
PLoS ONE 2017; 12: e0175451
